|Study Description:||The goal of this Phase 1 clinical research study is to learn the highest |
tolerable dose of the combination of the drugs BKM120 and olaparib or BYL719
and olaparib that can be given to patients with recurrent breast or ovarian
cancer. The safety of these drugs will also be studied.
BKM120, BYL719, and olaparib are both designed to block the growth and division
of cancer cells, which may cause the cells to die.